Eplontersen Sodium Patent Expiration
Eplontersen Sodium is Used for treating polyneuropathy associated with hereditary transthyretin-mediated amyloidosis. It was first introduced by Astrazeneca Ab
Eplontersen Sodium Patents
Given below is the list of patents protecting Eplontersen Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Wainua (autoinjector) | US10683499 | Compositions and methods for modulating TTR expression | Aug 25, 2034 | Astrazeneca Ab |
| Wainua (autoinjector) | US9127276 | Conjugated antisense compounds and their use | May 01, 2034 | Astrazeneca Ab |
| Wainua (autoinjector) | US9181549 | Conjugated antisense compounds and their use | May 01, 2034 | Astrazeneca Ab |
| Wainua (autoinjector) | US8101743 | Modulation of transthyretin expression | Apr 01, 2025 | Astrazeneca Ab |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Eplontersen Sodium's patents.
Latest Legal Activities on Eplontersen Sodium's Patents
Given below is the list recent legal activities going on the following patents of Eplontersen Sodium.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Term Extension Application under 35 USC 156 Filed | 16 Feb, 2024 | US9181549 |
| Patent Term Extension Application under 35 USC 156 Filed | 16 Feb, 2024 | US8101743 |
| Patent Term Extension Application under 35 USC 156 Filed | 16 Feb, 2024 | US10683499 |
| Patent Term Extension Application under 35 USC 156 Filed | 16 Feb, 2024 | US9127276 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 29 Nov, 2023 | US10683499 |
| FDA Final Eligibility Letter Critical | 14 Nov, 2023 | US8101743 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Jul, 2023 | US8101743 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 26 Apr, 2023 | US9181549 |
| transaction for FDA Determination of Regulatory Review Period | 28 Mar, 2023 | US8101743 |
| transaction for FDA Determination of Regulatory Review Period | 23 Mar, 2023 | US8101743 |
Eplontersen Sodium's Family Patents
